Eosinophilia: Secondary, clonal and idiopathic

Research output: Contribution to journalArticle

194 Citations (Scopus)

Abstract

Blood eosinophilia signifies either a cytokine-mediated reactive phenomenon (secondary) or an integral phenotype of an underlying haematological neoplasm (primary). Secondary eosinophilia is usually associated with parasitosis in Third World countries and allergic conditions in the West. Primary eosinophilia is operationally classified as being clonal or idiopathic, depending on the respective presence or absence of a molecular, cytogenetic or histological evidence for a myeloid malignancy. The current communication features a comprehensive clinical summary of both secondary and primary eosinophilic disorders with emphasis on recent developments in molecular pathogenesis and treatment.

Original languageEnglish (US)
Pages (from-to)468-492
Number of pages25
JournalBritish Journal of Haematology
Volume133
Issue number5
DOIs
StatePublished - Jun 2006

Fingerprint

Eosinophilia
Hematologic Neoplasms
Cytogenetics
Developing Countries
Cytokines
Phenotype
Neoplasms

Keywords

  • Diagnosis
  • FIP1L1-PDGFRA
  • Hypereosinophilic syndrome
  • Imatinib mesylate
  • Treatment

ASJC Scopus subject areas

  • Hematology

Cite this

Eosinophilia : Secondary, clonal and idiopathic. / Tefferi, Ayalew; Patnaik, Mrinal M; Pardanani, Animesh D.

In: British Journal of Haematology, Vol. 133, No. 5, 06.2006, p. 468-492.

Research output: Contribution to journalArticle

@article{67fa2205bade4c59a074d56f52a3c17b,
title = "Eosinophilia: Secondary, clonal and idiopathic",
abstract = "Blood eosinophilia signifies either a cytokine-mediated reactive phenomenon (secondary) or an integral phenotype of an underlying haematological neoplasm (primary). Secondary eosinophilia is usually associated with parasitosis in Third World countries and allergic conditions in the West. Primary eosinophilia is operationally classified as being clonal or idiopathic, depending on the respective presence or absence of a molecular, cytogenetic or histological evidence for a myeloid malignancy. The current communication features a comprehensive clinical summary of both secondary and primary eosinophilic disorders with emphasis on recent developments in molecular pathogenesis and treatment.",
keywords = "Diagnosis, FIP1L1-PDGFRA, Hypereosinophilic syndrome, Imatinib mesylate, Treatment",
author = "Ayalew Tefferi and Patnaik, {Mrinal M} and Pardanani, {Animesh D}",
year = "2006",
month = "6",
doi = "10.1111/j.1365-2141.2006.06038.x",
language = "English (US)",
volume = "133",
pages = "468--492",
journal = "British Journal of Haematology",
issn = "0007-1048",
publisher = "Wiley-Blackwell",
number = "5",

}

TY - JOUR

T1 - Eosinophilia

T2 - Secondary, clonal and idiopathic

AU - Tefferi, Ayalew

AU - Patnaik, Mrinal M

AU - Pardanani, Animesh D

PY - 2006/6

Y1 - 2006/6

N2 - Blood eosinophilia signifies either a cytokine-mediated reactive phenomenon (secondary) or an integral phenotype of an underlying haematological neoplasm (primary). Secondary eosinophilia is usually associated with parasitosis in Third World countries and allergic conditions in the West. Primary eosinophilia is operationally classified as being clonal or idiopathic, depending on the respective presence or absence of a molecular, cytogenetic or histological evidence for a myeloid malignancy. The current communication features a comprehensive clinical summary of both secondary and primary eosinophilic disorders with emphasis on recent developments in molecular pathogenesis and treatment.

AB - Blood eosinophilia signifies either a cytokine-mediated reactive phenomenon (secondary) or an integral phenotype of an underlying haematological neoplasm (primary). Secondary eosinophilia is usually associated with parasitosis in Third World countries and allergic conditions in the West. Primary eosinophilia is operationally classified as being clonal or idiopathic, depending on the respective presence or absence of a molecular, cytogenetic or histological evidence for a myeloid malignancy. The current communication features a comprehensive clinical summary of both secondary and primary eosinophilic disorders with emphasis on recent developments in molecular pathogenesis and treatment.

KW - Diagnosis

KW - FIP1L1-PDGFRA

KW - Hypereosinophilic syndrome

KW - Imatinib mesylate

KW - Treatment

UR - http://www.scopus.com/inward/record.url?scp=33646245681&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33646245681&partnerID=8YFLogxK

U2 - 10.1111/j.1365-2141.2006.06038.x

DO - 10.1111/j.1365-2141.2006.06038.x

M3 - Article

C2 - 16681635

AN - SCOPUS:33646245681

VL - 133

SP - 468

EP - 492

JO - British Journal of Haematology

JF - British Journal of Haematology

SN - 0007-1048

IS - 5

ER -